Fuisz Acquires Italian Drugmaker
USA-based Fuisz Technologies has announced its intention to purchaseItalian drugmaker Istoria Farmaceutici, but declined to disclose the terms of the transaction.
Istoria, a privately-held company based in Padova, primarily markets its drugs to gynecologists and pediatricians, with products including antihistamines, analgesics and antibiotics.
Hopes For Quicker Distribution Kenneth McVey, chief executive of Fuisz, said that together with the company's previously-announced acquisitions of pharmaceutical marketers in Ireland, France and the USA, "Istoria brings us a significant presence in the pharmaceutical market and will add to our international ability to quickly and efficiently distribute our products."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze